NCT05527288 is a NA clinical trial of Drug: [18F]florbetaben in Alzheimer Disease, sponsored by Sinotau Pharmaceutical Group.

Who is sponsoring NCT05527288?

NCT05527288 is sponsored by Sinotau Pharmaceutical Group.

What drugs are being tested in NCT05527288?

Interventions in NCT05527288: Drug: [18F]florbetaben.

What condition does NCT05527288 study?

NCT05527288 studies Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders.

Is NCT05527288 still recruiting?

NCT05527288 is currently completed. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT05527288

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

Completed NA Last updated 2 September 2022

What this trial tests

NA trial testing Drug: [18F]florbetaben in Alzheimer Disease in 50 participants. Completed in 12 September 2021.

Timeline

28 January 2021

Primary endpoint
12 September 2021

12 September 2021

Quick facts

Lead sponsor	Sinotau Pharmaceutical Group
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	28 January 2021
Primary completion	12 September 2021
Estimated completion	12 September 2021
Sites	1 location across China

Drugs / interventions tested

Drug: [18F]florbetaben — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Dementia — all drugs for Dementia →
Brain Diseases — all drugs for Brain Diseases →
Central Nervous System Diseases — all drugs for Central Nervous System Diseases →

Sponsor

Sinotau Pharmaceutical Group — full company profile →

Who can join

Adults 18 to 85, any sex, with Alzheimer Disease or Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with Alzheimer disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Sinotau Pharmaceutical Group trials

Trials by the same sponsor.

NCT07149831 — A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics o · Phase 1 · recruiting
NCT07115277 — Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cance · NA · recruiting
NCT07187895 — Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis · Phase 2 · terminated
NCT07115238 — Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD · Phase 3 · recruiting
NCT06398444 — A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05527288 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinotau Pharmaceutical Group
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing